Cell Therapy Limited has been rebranded to Celixir Limited reflecting its mission to discover,
develop and deliver life-saving and life-altering medicines to patients in need
CARDIFF 20 July, 2016 – Celixir, a leading British biotechnology company delivering breakthrough
regenerative medicines, has today rebranded from Cell Therapy. The change reflects the company’s
continued commitment to discovering, developing and delivering life-altering regenerative
medicines, and transforming patient care.
“The name Celixir combines ‘Cell’ with the Latin root word elixir to convey our vision to develop
curative regenerative medicines”, said Ajan Reginald, Chief Executive Officer of Celixir. “Adopting the
Celixir name signals the company’s evolution with an expanded portfolio of medicines, international
partnerships and robust financial position. It’s a fitting way to mark our 7th anniversary”.
To coincide with the rebrand, Celixir has unveiled a new logo and website http://www.celixir.com.
The new site offers the latest information about the company’s platform technology, product
portfolio, clinical evidence and stellar leadership, in an easy-to-use format.
The rebrand is effective immediately and will be implemented across all of the company’s platforms
and all future communications.
Celixir (formerly known as Cell Therapy Limited) is a private British regenerative medicine company
that discovers and develops life-saving and life-altering regenerative medicines for patients with the
greatest medical need. Celixir, founded in 2009, is made up of a world-class team of scientists and
biopharmaceutical executives, led by Nobel Laureate Professor Sir Martin Evans and former Roche
Global Head of Emerging Technologies, Ajan Reginald. Celixir’s unique platform technology allows
them to adopt an ‘off-the-shelf’ approach to deliver regenerative medicines to patients.